The application of human KRAS G12C & SOS1 Binding assay kit in KRAS-targeted therapy research

I. Introduction

As one of the first discovered human oncogenes, KRAS is frequently mutated in various malignancies such as pancreatic cancer, colorectal cancer, and lung cancer, driving tumor initiation and progression. Due to its unique protein structure, KRAS was long considered an "undruggable" target until the groundbreaking development of KRAS G12C inhibitors recently changed this paradigm. This article systematically reviews the molecular biological characteristics, regulatory networks, oncogenic mechanisms, and therapeutic strategies of KRAS, aiming to provide references for a deeper understanding of KRAS function and the development of more effective treatment approaches.

II. Molecular Biological Characteristics of KRAS Protein

As a small GTPase, KRAS protein plays a key role as a molecular switch in cellular signal transduction, with its function precisely regulated at multiple levels from gene transcription to protein degradation.

At the transcriptional level, the G-quadruplex structure in the KRAS promoter region can act as a transcription regulatory factor influencing gene expression. Small molecule ligands like berberine can stabilize this structure, reducing KRAS mRNA levels. At the post-transcriptional level, KRAS undergoes alternative splicing to produce two isoforms, KRAS4A and KRAS4B, which differ in their C-terminal hypervariable regions and may play distinct roles in oncogenesis. MicroRNAs such as miR-96 can directly target KRAS mRNA to suppress its expression. At the translational level, the KRAS gene is rich in rare codons, naturally limiting its translation efficiency—a low-expression characteristic with complex implications in tumorigenesis.

KRAS protein function highly depends on its proper localization at the plasma membrane. Newly synthesized KRAS first undergoes farnesylation modification, the initial step for membrane anchoring. Mislocalized KRAS can be recognized and captured by PDEδ, then transported back and enriched at the plasma membrane via SNARE protein-mediated vesicular trafficking. Glycosphingolipids are crucial for maintaining KRAS localization at the plasma membrane.

KRAS protein abundance is tightly regulated by the ubiquitin-proteasome system. Deubiquitinating enzymes like JOSD2 can remove ubiquitin chains from KRAS, protecting it from degradation and extending its half-life. Conversely, impaired LZTR1-mediated degradation pathways lead to elevated wild-type KRAS levels, driving endogenous resistance to RAS inhibitors.

III. KRAS Signaling Pathways and Oncogenic Mechanisms

In physiological states, KRAS protein toggles between inactive and active states by binding GDP or GTP. When KRAS genes mutate, the GTPase-activating protein (GAP)-mediated GTP hydrolysis process is blocked, causing KRAS to remain in a GTP-bound active conformation, persistently activating downstream RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways to drive tumor cell proliferation, survival, invasion, and metastasis.

Different KRAS mutation subtypes may exhibit variations in signaling intensity and downstream pathway preferences. Common mutations like G12C, G12D, G12V, and G13D all impair GTP hydrolysis but may differ subtly in GAP sensitivity and effector molecule binding affinity, potentially explaining the distribution differences of mutation subtypes across cancer types and their varied treatment responses.

IV. KRAS-Targeted Therapeutic Strategies

The successful development of KRAS G12C inhibitors (e.g., sotorasib, adagrasib) marks a milestone in targeted therapy. Their mechanism relies on recognizing the allosteric pocket of the KRAS G12C mutant in its GDP-bound state, covalently locking the mutant protein into an inactive conformation. This breakthrough proves that inhibiting KRAS function by targeting non-active conformations of specific mutation subtypes is a feasible strategy.

Building on this success, inhibitor development for other KRAS mutation subtypes is rapidly advancing. As the most common mutation subtype in pancreatic cancer, KRAS G12D inhibitors are highly anticipated, with strategies shifting toward non-covalent inhibitors (e.g., MRTX1133) and protein degraders (PROTACs). KRAS G12V inhibitor development also faces challenges, though recent progress has been made through indirect approaches like synthetic lethal target screening (e.g., ELOVL6).

Indirect targeting strategies include intervening in upstream regulators or downstream effector pathways. SHP2 inhibitors block receptor tyrosine kinase signal transmission to KRAS, synergistically enhancing KRAS inhibitor efficacy. SOS1 inhibitors interfere with KRAS GTP/GDP exchange, limiting its activation. Downstream pathway inhibitors like MEK and ERK inhibitors can block KRAS mutation-activated signal output.

Proteolysis-targeting chimera (PROTAC) technology offers a novel approach for targeting KRAS. PROTAC molecules simultaneously bind KRAS protein and E3 ubiquitin ligases (e.g., CRBN, VHL), inducing KRAS ubiquitination and proteasomal degradation to completely eliminate its oncogenic function. Currently, degraders targeting KRAS G12C are in preclinical studies.

V. Application of Human KRAS G12C & SOS1 Binding Kit in Drug Development

In KRAS-targeted drug development, accurately assessing KRAS protein interactions with upstream regulators is crucial. The Human KRAS G12C & SOS1 Binding Kit (GDP load) provides a standardized detection tool for this research.

As a guanine nucleotide exchange factor (GEF), SOS1 is a key regulatory protein in KRAS activation, catalyzing the transition of KRAS from GDP-bound to GTP-bound states. Based on the conformational features of KRAS G12C in its GDP-bound state, this kit quantitatively detects KRAS G12C-SOS1 binding activity using time-resolved fluorescence resonance energy transfer (TR-FRET) technology.

In drug development, the kit can evaluate whether candidate compounds function by disrupting KRAS-SOS1 interactions, screen inhibitors that block SOS1-mediated GTP exchange, and validate whether secondary KRAS mutations arising from resistance affect SOS1 binding, providing experimental evidence for understanding resistance mechanisms.

VI. Outlook

KRAS-targeted therapy has achieved revolutionary progress over the past decade, transitioning from "undruggable" to clinical translation. Future research directions include: deepening understanding of the biological characteristics of different KRAS mutation subtypes; optimizing pharmacokinetic properties of existing inhibitors; exploring combination therapy strategies (e.g., with SHP2 inhibitors, PD-1 inhibitors, chemotherapy) to delay resistance; developing novel protein degraders for more complete target inhibition; and implementing dynamic monitoring of resistance mutations through liquid biopsy technologies. As research advances, precision therapy for KRAS-mutant tumors will gradually mature, offering better clinical outcomes for patients.